Education
About Us
Working with TipRanks
Follow Us
Octave Specialty Group (OSG)
NYSE:OSG
Top Page
Octave Specialty Group
(NYSE:OSG)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.00
▲(12.15% Upside)
Action:ReiteratedDate:01/13/26
The score is primarily held down by very poor TTM financial performance (large losses and negative cash flow) and a clearly bearish technical trend (price below major moving averages with negative MACD). Offsetting this, the earnings call indicates meaningful strategic actions (asset sale, buybacks, cost reductions, and growth initiatives), and the balance sheet shows improved leverage, but operating results remain the key risk.
Octave Specialty Group (OSG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$234.39M
Dividend YieldN/A
Average Volume (3M)749.19K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth-37.46%
EPS Growth-117.36%
CountryUS
Employees380
SectorFinancial
Sector Strength70
IndustryInsurance - Specialty
Share Statistics
EPS (TTM)-0.02
Shares Outstanding43,812,035
10 Day Avg. Volume528,569
30 Day Avg. Volume749,192
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.69
Price to Sales (P/S)2.52
P/FCF Ratio779.75
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue2.92
Enterprise Value/Gross Profit-17.19
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$15.00Price Target Upside180.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.29
Revenue Forecast (FY)$69.79M
Octave Specialty Group Business Overview & Revenue Model
Company DescriptionOctave Specialty Group, Inc. operates as a financial services holding company. It operates in two segments, Specialty Property and Casualty Insurance; and Insurance Distribution. The Specialty Property and Casualty Insurance segment provides specialty property and casualty program insurance with a focus on commercial and personal liability risks. The Insurance Distribution segment offers specialty property and casualty insurance distribution services, which include managing general agents, underwriters, insurance broker, and other distribution and underwriting businesses. The company was formerly known as Ambac Financial Group, Inc. and changed its name to Octave Specialty Group, Inc. in November 2025. The company was founded in 1971 and is headquartered in New York, New York.
How the Company Makes MoneyAmbac Financial generates revenue primarily through the issuance of financial guarantees and credit enhancements for municipal bonds and structured finance products. The company collects premiums from issuers for providing these guarantees, which are based on the risk associated with the underlying debt. Additionally, Ambac earns income from investment income generated from its own portfolio of investments, which include fixed-income securities. The company may also receive fees for advisory services and asset management. Partnerships with municipalities and financial institutions further bolster its revenue streams, as these relationships help Ambac to secure a steady flow of business in both the public and private sectors.
Octave Specialty Group Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call presented a constructive growth story driven by a rapidly scaling Insurance Distribution platform, strong organic and Ventures revenue growth, margin improvement in distribution, accretive high-margin acquisition (ArmadaCare), AI/tech differentiation, and clear 2026 guidance. These positives were offset by transitional reported losses driven by acquisition and one-time corporate costs, impairments, start-up investment drag, and near-term pressure in some P&C pricing areas. Management framed the negatives as largely transactional and part of a multi-year scaling strategy, with several metrics (adjusted EBITDA, distribution margins, Ventures growth, combined ratio) trending favorably toward management targets.Q4-2025 Updates
Positive Updates
Strong Insurance Distribution Revenue Growth
Insurance Distribution business revenue grew 65% over 2024, including 14% organic growth (note: excludes 8 months of Octave Ventures and ArmadaCare acquisition).
Octave Ventures Rapid Expansion
Octave Ventures standalone organic revenue growth increased from ~18% in 2024 to ~47% in 2025, reflecting strong incubator performance and pipeline.
Quarterly Production and Commission Growth
In Q4 2025, Insurance Distribution premium production grew 9%, commission revenue grew 13%, and organic revenue increased just over 8% year-over-year.
Adjusted EBITDA Improvement (Distribution and Consolidated Adjusted)
Adjusted EBITDA from continuing operations rose to $1.4M in Q4 2025 vs $0.5M in Q4 2024. Insurance Distribution adjusted EBITDA to shareholders increased to just over $7M from just over $5M, a 33% increase.
Improving Distribution Margins
Insurance Distribution adjusted EBITDA margin improved to 15% in Q4 2025 from 12% a year earlier and operating basis adjusted EBITDA was over $10M at a 22.6% margin (vs just under $10M and 22.3% prior year), trending toward mid-20s target.
ArmadaCare Acquisition Adds High-Margin A&H Scale
ArmadaCare acquired in Q4 2025 enhances A&H exposure and adds recurring revenue with attractive EBITDA margins of over 40%; integration progressed ahead of schedule and early performance exceeded expectations (2 months contribution in Q4).
Everspan Repositioning Showing Improvement
After repositioning, Everspan reported an effective loss & LAE ratio (including sliding scale commissions) of 62.9% in Q4 2025 vs 66.8% in Q4 2024 (down nearly 4 percentage points). Combined ratio fell below 100% to 99.4% for the first time this year with expectation to remain <100% in 2026.
Everspan Premium Growth
Everspan gross premiums written rose 34% to $80M in Q4 2025; net premiums written improved from negative $3M in prior year to $23M; net earned premium was roughly flat year-over-year.
Corporate Cost Reduction Momentum
Adjusted corporate G&A decreased to $7.5M in Q4 2025 from $8.8M in Q4 2024. Selected corporate expense reduction initiatives are expected to generate ~ $17M of reported expense savings and > $10M impact on adjusted corporate EBITDA when fully complete.
Clear 2026 Guidance and Growth Targets
2026 guidance: Insurance Distribution organic revenue growth of at least 20% and adjusted EBITDA ~ $40M; Specialty Insurance GWP ~ $410M and adjusted EBITDA ~ $7.5M; corporate adjusted expenses below $30M; consolidated adjusted net income ~ $0.50 per share.
Technology and AI-Driven Differentiation
Launched proprietary AI platform 'Hammurabi' for medical stop-loss, contributing to record ESL results; management is integrating AI/data tools across MGAs to improve risk selection, pricing and operational efficiency.
Embedded Growth Pipeline of New MGAs
9 of 22 MGAs were launched in 2024-2025; over 40% of MGAs are in early growth stages with many expected to contribute materially to future organic revenue and earnings; management expects most startup losses to improve with all but 2 of 6 negative-EBITDA entities anticipated to be breakeven/profitable by Q4 2026.
Negative Updates
Reported Net Loss and Per-Share Decline
Q4 2025 net loss to shareholders of $30M ($0.84 per share) versus a net loss of $22M ($0.56 per share) in Q4 2024, driven by acquisition costs, exit from the financial guarantee business, restructuring and an impairment.
Large One-Time Corporate Expenses and Impairments
Reported corporate G&A rose to $25M in Q4 2025 from $14.6M in Q4 2024 due to acquisition/integration costs (~$7.8M), an impairment of a legacy minority investment ($3.1M) and restructuring/expense reduction initiatives (~$7.6M).
Everspan Profit Metrics Declined on a Reported Basis
Everspan pretax income fell to $1.3M in Q4 2025 from $2.6M in Q4 2024; adjusted EBITDA declined to $1.5M from $2.7M, driven by a $1.8M revenue reduction and higher G&A as part of repositioning.
Increase in Net Loss & LAE Ratio (Raw)
Net loss and LAE ratio was 61.8% in Q4 2025, up from 51.9% in Q4 2024 (though management highlights sliding scale commission adjustments that change the effective comparison).
Modest Overall Revenue Growth and Headwinds
Total revenues were up only 5% to just under $47M in Q4 2025 versus Q4 2024, impacted by about $4M decline in profit commissions and FX gains.
Start-Up Investment Drag on Adjusted EBITDA
Investment in start-up MGAs created a drag on total adjusted EBITDA of just under $3M (approximately $1.5M to shareholders) in Q4 2025; six entities produced negative EBITDA in the quarter.
High G&A Ratio and Near-Term Pressure
Company G&A ratio was 11.7% in Q4 2025, higher than desired, with expectations that it will recede as scale is achieved (management targets ~ $500M GWP to reach scale by 2028).
Transitional Nature of ArmadaCare Benefits in Q4
ArmadaCare contributed only two months of results in Q4 2025; associated acquisition/integration costs also pressured reported results in the quarter.
Softening Pricing in Parts of P&C Market
Management noted 5%-10% rate reductions in non-cat property programs and mixed pricing across casualty and non-cat property, signaling pressure in certain P&C segments despite pockets of rate strength.
Company Guidance
Octave guided to tangible 2026 targets: Insurance Distribution is expected to deliver at least 20% organic revenue growth and roughly $40 million of adjusted EBITDA (with segment margins trending toward mid-20s over time; Q4 '25 adj. EBITDA margin was 15% and operating basis 22.6%), Specialty Insurance (including Everspan) is projected to write about $410 million of gross written premiums and produce approximately $7.5 million of adjusted EBITDA, corporate adjusted expenses are expected to be below $30 million, and consolidated adjusted net income is targeted at about $0.50 per share; management also said NCI buy-ins this year should be less than $50 million (to be funded from cash and modest incremental borrowing), net investment income should be flat to marginally higher, equity-based comp should be down a few million versus 2025, ArmadaCare contributes >40% EBITDA margins and A&H earnings are seasonally weighted (about 60% in Q1), and corporate expense-reduction initiatives are estimated to yield roughly $17 million of reported savings (and >$10 million benefit to adjusted corporate EBITDA) when fully realized.Octave Specialty Group Financial Statement Overview
Summary
Income statement and cash flow are very weak in TTM, with sharply deteriorated profitability (very large net loss and deeply negative margins) and negative operating/free cash flow. The main offset is an improved leverage profile (reported total debt at 0 in TTM) and a sizable equity base, but returns on equity are extremely poor due to losses.Income Statement
Profitability has deteriorated sharply in TTM (Trailing-Twelve-Months): revenue is down (-3.3% growth) and both gross profit and operating profit are deeply negative, culminating in a very large net loss (net margin around -787%). While 2023 showed modest profitability, results swung materially negative in 2024 and worsened further in TTM, signaling weak earnings quality and high volatility despite prior periods of growth.14
Very Negative
Balance Sheet
Leverage looks significantly improved versus earlier years: total debt is reported at 0 in TTM (Trailing-Twelve-Months) and was modest in 2024 (debt-to-equity ~0.18), a major step down from very high leverage in 2020–2023. Equity remains sizable (about $843M in TTM), supporting the capital base; however, returns are very poor (TTM return on equity about -91%) due to heavy losses, which is the key balance-sheet risk despite the lower reported debt load.57
Neutral
Cash Flow
Cash generation is weak and trending worse: TTM (Trailing-Twelve-Months) operating and free cash flow are both negative (~-$35M), and free cash flow growth is sharply down. 2023 showed strong positive operating/free cash flow, but 2024 collapsed to near break-even, and TTM turned negative again—indicating inconsistent cash conversion and elevated funding/earnings risk while losses persist.18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.13M | 235.81M | 124.73M | 53.61M | 247.00M | 156.00M |
| Gross Profit | -16.86M | 98.65M | 47.99M | 24.36M | 319.00M | -69.00M |
| EBITDA | -141.81M | -30.52M | -18.99M | -31.91M | 246.00M | -160.00M |
| Net Income | -780.16M | -556.45M | 3.63M | 521.25M | -17.00M | -437.00M |
Balance Sheet | ||||||
| Total Assets | 2.15B | 8.06B | 8.43B | 7.97B | 12.30B | 13.22B |
| Cash, Cash Equivalents and Short-Term Investments | 478.69M | 331.90M | 354.96M | 1.93B | 1.85B | 2.83B |
| Total Debt | 0.00 | 150.00M | 3.48B | 3.75B | 6.45B | 7.23B |
| Total Liabilities | 1.00B | 6.86B | 7.00B | 6.65B | 11.19B | 12.07B |
| Stockholders Equity | 843.38M | 856.91M | 1.36B | 1.25B | 1.04B | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | -34.95M | 762.00K | 200.00M | 70.37M | -131.00M | -353.00M |
| Operating Cash Flow | -34.95M | 762.00K | 200.00M | 70.37M | -131.00M | -175.00M |
| Investing Cash Flow | 112.78M | -166.37M | 435.00M | -41.16M | 776.00M | 432.00M |
| Financing Cash Flow | -78.88M | 194.22M | -423.00M | -19.23M | -657.00M | -303.00M |
Octave Specialty Group Technical Analysis
5.35
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSG, the sentiment is undefined. The current price of 5.35 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for OSG.
Octave Specialty Group Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
* Financial Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.